Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
2 competitors in Influenza, Human
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Dectova
Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ?6 months) when: The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or Other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Dectova should be used in accordance with official guidance.
View on EMADental Caries
Hepatitis B
Pulmonary Disease, Chronic Obstructive
Acute Coronary Syndrome
Infections, Meningococcal